Business Of Biotech · October 2026
Roeding, a biotech founder, was listing the facts he thinks show how squeezed US biotech funding has become. The first was his figure that 87.5% of venture dollars this year are going to AI. The numbers are his.
…awesome. I'm a big believer in capitalism. But there are certain situations where the system is failing us that is otherwise so efficient. And that is called boom and bust cycles in biotech. The boom and bust cycles in biotech are more extreme than I believe in any other innovation-based industry.
Yeah, and we're just coming out of a long bus cycle, right? Hopefully coming out. Yeah. Thank you.
So the last four years, not this year, but the prior four years, have been the biggest bust, I think, in the last over 20 years. Right. So now we're this happened after the pandemic. It was sort of like an aftershock of this overhype situation, and the all the money went away. But now let me give you three major facts that make paint this picture how extreme this is right now. Number one, guess how many percent of venture capital dollars this year are going to AI versus to other parts of the of innovation? Oh, I've 10 to 1. 87.5%. Wow. Okay. That means everyone else gets 12 and a half. Now, fortunately, Earli is on the intersection of bio and AI. So that's great. It's special, but not every biotech is, most biotechs aren't. So 12.5% left for everything else. That's number one. Number two. Five years ago, less than five percent of the licensing dollars from pharma companies went to China. This year, it will be two-thirds.
Yeah.
Two-thirds. One third is left for US firms or anywhere else in the world outside of China. That is a dramatic shift. What are they buying? They're not just buying cheap knockoffs, they're buying innovation. Right. So, how come there's so much innovation to buy? And the answer is a sustained, flat…
The valley of death, that's right.